Trials / Completed
CompletedNCT00444535
Lapatinib and Bevacizumab for Metastatic Breast Cancer
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib | 1500 mg oral lapatinib (once daily) |
| DRUG | bevacizumab | 10 mg/kg intravenous bevacizumab (every two weeks) |
Timeline
- Start date
- 2007-02-27
- Primary completion
- 2008-07-22
- Completion
- 2020-06-19
- First posted
- 2007-03-08
- Last updated
- 2021-10-25
- Results posted
- 2009-08-20
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00444535. Inclusion in this directory is not an endorsement.